Choose a Drug ! Aciphex Acomplia Actos Acyclovir Allegra Alli Diet Drug Altace Ambien Amoxicillin Atenolol Ativan Augmentin Avandia Avapro Baclofen Bactrim Biaxin Celebrex Celexa Cephalexin Champix Cialis Cipro Claritin D Clomid Coreg Depakote Diflucan Dilantin Diovan Doxycycline Effexor XR Elavil Estradiol Flomax Flonase Fluoxetine Folic Acid Fosamax Glucophage Hydroxyzine Ibuprofen Imitrex Keflex Lamisil Lasix Levaquin Levitra Lexapro Lipitor Mobic Naproxen Neurontin Nexium Norvasc Omeprazole Paxil Plavix Premarin Prevacid Promethazine Propecia Proscar Protonix Reductil Reglan Remeron Risperdal Singulair Sonata Synthroid Tamiflu Topamax Trazodone Ultra "C" tabs Ultra "L" tabs Ultra "V" tabs Ultram Viagra Wellbutrin Xenical Zithromax Zocor Zoloft Zyban Zyprexa Zyrtec

September 2007 August 2007 July 2007 June 2007 May 2007 April 2007 March 2007 February 2007 January 2007 December 2006 November 2006 October 2006 September 2006 August 2006 July 2006 June 2006 May 2006 April 2006 March 2006 February 2006

Opt-in for Free Newsletter, special discount offers, drugs information & latest pharmacy news.

Millions spent on diabetes — but no strategy in place

IRELAND spends hundreds of millions of euro annually treating preventable complications in diabetes patients, but has no national strategy to tackle the growing health issue.

A comparison of 15 EU countries shows Ireland has the fourth-highest spend on direct medical intervention for diabetes care despite having the lowest prevalence rate of diabetes in adults (3.4%). The figures, contained in an audit of diabetes rates and care in all 25 EU states, estimates Ireland spends up to 10% of its €11 billion health budget each year on diabetes and related health issues, which include cardiovascular disease, blindness, lower limb amputation and renal failure. Yet the Netherlands where adult prevalence rates are similar to Ireland (3.7%) has the lowest healthcare diabetes costs, spending just 2.5 % of its total healthcare budget on the illness.

Diabetes Federation of Ireland (DFI) chief executive Kieran O'Leary said the lack of a properly resourced framework to tackle diabetes means the Government is spending hundreds of millions on treating largely manageable complications.

Source:http://www.irishexaminer.com